期刊文献+

武汉地区33家医院2008~2010年5-HT_3受体拮抗药应用分析 被引量:2

Analysis of 5-HT_3 Receptor Antagonists in Wuhan Area during the Period 2008-2010
下载PDF
导出
摘要 目的:研究5-HT_3受体拮抗药在武汉地区的应用情况和发展趋势。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对武汉地区33家医院2008~2010年5-HT_3受体拮抗药有关数据进行统计分析。结果:5-HT_3受体拮抗药销售金额逐年增加,托烷司琼使用频度的构成比最高,帕洛诺司琼的销售金额与使用频度增长迅速。结论:第一代5-HT_3受体拮抗药仍然是化疗呕吐治疗的一线用药,第二代5-HT_3受体拮抗药在治疗化疗呕吐领域越来越受到重视。 Objective: To evaluate the current situation and the developing trend of 5-HT3 receptor'antagonists used in 33 hospital of Wuhan during the period of 2008-2010. Method :The 5-HT3 receptor antagonists were statistically analyzed in respect to consumption sum, DDDs and daily costs. Result:During the 3 years, consumption sum of 5-HT3 receptor antagonists were yearly increasing. Tropisetron ranked the first in constituent ratios of consumption sum. The market of palonosetron showed a rapid increasing tendency. Conclusion:The first generation 5-HT3 receptor antagonists are the firstchoice drugs in the clinic, while the second generation 5-HT3 receptor antagonists will be gradually accepted by doctors.
出处 《药物流行病学杂志》 CAS 2011年第10期525-527,共3页 Chinese Journal of Pharmacoepidemiology
关键词 5-HT3受体拮抗药 限定日剂量 用药频度 日用药金额 5-HT3 receptor antagonists Defined daily dose DDDs Daily drug cost
  • 相关文献

参考文献6

二级参考文献30

  • 1郝红兵.北京地区2002年~2004年抗抑郁药应用分析[J].中国医院用药评价与分析,2006,6(2):81-83. 被引量:12
  • 2Einhorn LH,Brames MJ,Dreicer R,et al.Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer[J].Support Care Cancer,2007,15(11):1293-13130.
  • 3Rojas C,Thomas AG,Alt J,et al.Palonosetron triggers 5-HT(3)receptor internalization and causes prolonged inhibition of receptor function[J].Eur J Pharmacol,2010,626(2/3):193-199.
  • 4Segawa Y,Aogi K,Inoue K,et al.A phase Ⅱ dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy,including anthracyeline and cyclophosphamidebased chemotherapy[J].Ann Oncol,2009 20(11):1874-1880.
  • 5Maemondo M,Masuda N,Sekine I,et al.A phase Ⅱ study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy[J].Ann Oncol,2009,20(11):1860-1866.
  • 6Navari RM.Palonosetron:a second generation 5-hydroxytryptamine 3 receptor antagonist[J].Expert Opin Drug Metab Toxicol,2009,5(12):1577-1586.
  • 7Aapro M,Fabi A,Nolè F,et al.Double-blind,randomised,controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy[J].Ann Oncol,2010,21(5):1083-1088.2001,22(1):491-493.
  • 8Ettinger D5,Bierman PJ,Bradbury B,et al.Antiemesis[J].J Natl Compr Canc Netw,2007,5(1):12-33.
  • 9Cohen L,de Moor CA,Eisenberg P,et al.Chemotherapy-induced nausea and vomiting:incidence and impact on patient quality of life at community oncology settings[J].Support Care Cancer,2007,15(5):497-503.
  • 10Bloechl-Daum B,Deuson RR,Mavros P,et al.Delayed nausea and vomiting continue to reduce patients'quality of life after highly and moderately emetogeic chemotherapy despite antiemetic treatment[J].J Clin Oncol,2006,24(27):4472-4478.

共引文献16

同被引文献40

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部